149 related articles for article (PubMed ID: 27312965)
1. Management of anaplastic lymphoma kinase positive orbito-conjunctival inflammatory myofibroblastic tumor with crizotinib.
Kiratli H; Uzun S; Varan A; Akyüz C; Orhan D
J AAPOS; 2016 Jun; 20(3):260-3. PubMed ID: 27312965
[TBL] [Abstract][Full Text] [Related]
2. Complete and Repeated Response of a Metastatic ALK-rearranged Inflammatory Myofibroblastic Tumor to Crizotinib in a Teenage Girl.
Gaudichon J; Jeanne-Pasquier C; Deparis M; Veyssière A; Heyndrickx M; Minckes O; Orbach D
J Pediatr Hematol Oncol; 2016 May; 38(4):308-11. PubMed ID: 26808369
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant crizotinib in advanced inflammatory myofibroblastic tumour with ALK gene rearrangement.
Rafee S; Elamin YY; Joyce E; Toner M; Flavin R; McDermott R; Sheehy N; Hennessy B; O'Byrne K; Gleeson N; Osman N
Tumori; 2015 Apr; 101(2):e35-9. PubMed ID: 25744866
[TBL] [Abstract][Full Text] [Related]
4. A case report of epithelioid inflammatory myofibroblastic sarcoma with RANBP2-ALK fusion gene treated with the ALK inhibitor, crizotinib.
Kimbara S; Takeda K; Fukushima H; Inoue T; Okada H; Shibata Y; Katsushima U; Tsuya A; Tokunaga S; Daga H; Okuno T; Inoue T
Jpn J Clin Oncol; 2014 Sep; 44(9):868-71. PubMed ID: 25028698
[TBL] [Abstract][Full Text] [Related]
5. Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.
Butrynski JE; D'Adamo DR; Hornick JL; Dal Cin P; Antonescu CR; Jhanwar SC; Ladanyi M; Capelletti M; Rodig SJ; Ramaiya N; Kwak EL; Clark JW; Wilner KD; Christensen JG; Jänne PA; Maki RG; Demetri GD; Shapiro GI
N Engl J Med; 2010 Oct; 363(18):1727-33. PubMed ID: 20979472
[TBL] [Abstract][Full Text] [Related]
6. Epithelioid inflammatory myofibroblastic sarcoma treated with ALK inhibitor: a case report and review of literature.
Liu Q; Kan Y; Zhao Y; He H; Kong L
Int J Clin Exp Pathol; 2015; 8(11):15328-32. PubMed ID: 26823889
[TBL] [Abstract][Full Text] [Related]
7. More on crizotinib.
Orenstein JM
N Engl J Med; 2011 Feb; 364(8):777; author reply 778-9. PubMed ID: 21345112
[No Abstract] [Full Text] [Related]
8. Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children's Oncology Group Study.
Mossé YP; Voss SD; Lim MS; Rolland D; Minard CG; Fox E; Adamson P; Wilner K; Blaney SM; Weigel BJ
J Clin Oncol; 2017 Oct; 35(28):3215-3221. PubMed ID: 28787259
[TBL] [Abstract][Full Text] [Related]
9. Crizotinib in ALK
Theilen TM; Soerensen J; Bochennek K; Becker M; Schwabe D; Rolle U; Klingebiel T; Lehrnbecher T
Pediatr Blood Cancer; 2018 Apr; 65(4):. PubMed ID: 29286567
[TBL] [Abstract][Full Text] [Related]
10. ALK inhibition in two emblematic cases of pediatric inflammatory myofibroblastic tumor: Efficacy and side effects.
Brivio E; Zwaan CM
Pediatr Blood Cancer; 2019 May; 66(5):e27645. PubMed ID: 30697903
[TBL] [Abstract][Full Text] [Related]
11. Aggressive Metastatic Inflammatory Myofibroblastic Tumor After Allogeneic Stem Cell Transplant With Fatal Pulmonary Toxicity From Crizotinib.
Shash H; Stefanovici C; Phillips S; Cuvelier GD
J Pediatr Hematol Oncol; 2016 Nov; 38(8):642-645. PubMed ID: 27271810
[TBL] [Abstract][Full Text] [Related]
12. ALK negative inflammatory myofibroblastic tumor of the orbit: a masquerading entity.
Dutta V; Manoj MG; Malik A; Kumar P
Indian J Ophthalmol; 2014 May; 62(5):627-9. PubMed ID: 24881614
[TBL] [Abstract][Full Text] [Related]
13. How long should we continue crizotinib in ALK translocation-positive inflammatory myofibroblastic tumors? Long-term complete response with crizotinib and review of the literature.
Alan O; Kuzhan O; Koca S; Telli TA; Basoglu T; Ercelep O; Filinte D; Sengul Y; Arikan H; Kaya S; Babacan NA; Dane F; Yumuk PF
J Oncol Pharm Pract; 2020 Jun; 26(4):1011-1018. PubMed ID: 31615346
[TBL] [Abstract][Full Text] [Related]
14. Inflammatory myofibroblastic tumor of the conjunctiva: response to chemotherapy with low-dose methotrexate and vinorelbine.
Favini F; Resti AG; Collini P; Casanova M; Meazza C; Trecate G; Ferrari A
Pediatr Blood Cancer; 2010 Mar; 54(3):483-5. PubMed ID: 19890966
[TBL] [Abstract][Full Text] [Related]
15. Infantile inflammatory myofibroblastic tumors: clinicopathological and molecular characterization of 12 cases.
Lopez-Nunez O; John I; Panasiti RN; Ranganathan S; Santoro L; Grélaud D; Wu T; Buccoliero AM; Casanova M; Alaggio R; Surrey LF
Mod Pathol; 2020 Apr; 33(4):576-590. PubMed ID: 31690781
[TBL] [Abstract][Full Text] [Related]
16. Crizotinib as a personalized alternative for targeted anaplastic lymphoma kinase rearrangement in previously treated patients with non-small-cell lung cancer.
Guo L; Zhang H; Shao W; Chen B
Drug Des Devel Ther; 2015; 9():5491-7. PubMed ID: 26491259
[TBL] [Abstract][Full Text] [Related]
17. Anaplastic lymphoma kinase-negative pulmonary inflammatory myofibroblastic tumor with multiple metastases and its treatment by Apatinib: A case report.
Liu Q; Wei J; Liu X; Wang J
Medicine (Baltimore); 2019 Dec; 98(52):e18414. PubMed ID: 31876714
[TBL] [Abstract][Full Text] [Related]
18. Inflammatory myofibroblastic tumor: molecular landscape, targeted therapeutics, and remaining challenges.
Mahajan P; Casanova M; Ferrari A; Fordham A; Trahair T; Venkatramani R
Curr Probl Cancer; 2021 Aug; 45(4):100768. PubMed ID: 34244015
[TBL] [Abstract][Full Text] [Related]
19. Crizotinib in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma in the setting of renal insufficiency: a case report.
Kothari S; Ud-Din N; Lisi M; Coyle T
J Med Case Rep; 2016 Jun; 10():176. PubMed ID: 27301488
[TBL] [Abstract][Full Text] [Related]
20. Infratemporal inflammatory myofibroblastic tumour with orbital extension.
Chow SP; Nastri A; Hardy T
Clin Exp Ophthalmol; 2010 Oct; 38(7):727-30. PubMed ID: 20497435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
